While many studies aiming to treat NAFLD through bile metabolism concentrate on inhibiting bile synthesis in the liver using FXR agonists [51,52], our results show that PRE led to an increase in bile synthesis, a pattern typically observed when bile acid reabsorption from the intestine is inhibited [53,54]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.